Table. Baseline Clinical Characteristics of the Study Samplea.
| Characteristic | Patients | P valueb | |
|---|---|---|---|
| Deferred AVR (n = 46) | Expedited AVR (n = 25) | ||
| Age, mean (SD), y | 77.2 (7.8) | 79.6 (6.7) | .18 |
| Female | 22 (47.8) | 10 (40.0) | .62 |
| BMI, mean (SD)c | 27.2 (5.2) | 28.2 (4.2) | .46 |
| Symptoms | |||
| NYHA class III or IVd | 13 (29.6) | 17 (68.0) | .003 |
| CCS grade III or IV | 1 (2.2) | 1 (4.0) | >.99 |
| Syncope | 4 (8.7) | 1 (4.0) | .65 |
| COVID-19 assessment | |||
| Fevere | 0 | 1 (4.0) | .42 |
| Coughe | 3 (6.5) | 1 (4.0) | .63 |
| Sore throatf | 0 | 0 | NA |
| SARS-CoV-2 PCR testg | 6 (13.0) | 12 (48.0) | .02 |
| Risk assessment: STS-PROM score, mean (SD)b | 3.3 (2.6) | 2.9 (2.0) | .59 |
| Medical conditions | |||
| Diabetes | 14 (30.4) | 9 (36.0) | .79 |
| Hypercholesterolemia | 28 (60.9) | 11 (44.0) | .21 |
| Hypertension | 41 (89.1) | 23 (92.0) | >.99 |
| Coronary artery disease | 14 (30.4) | 8 (32.0) | >.99 |
| COPD | 1 (2.2) | 1 (4.0) | >.99 |
| GFR <60 mL/min | 19 (41.3) | 10 (40.0) | >.99 |
| History of atrial fibrillation | 9 (19.6) | 9 (36.0) | .16 |
| Previous stroke or TIA | 2 (4.3) | 4 (16.0) | .17 |
| Echocardiography findings | |||
| Aortic valve, mean (SD) | |||
| Gradient, mean (SD), mm Hg | 40.6 (13.3) | 50.5 (13.2) | .003 |
| Area, cm2d | 0.8 (0.2) | 0.7 (0.2) | .11 |
| LVEF, mean (SD), % | 57.9 (14.5) | 58.9 (13.1) | .78 |
| Multivalvular heart disease | 7 (15.2) | 1 (4.0) | .24 |
| Mitral regurgitation, moderate or severe | 7 (15.2) | 1 (4.0) | .24 |
| Tricuspid regurgitation, moderate or severe | 2 (4.3) | 0 | .54 |
| AVR | |||
| Transcatheter | 4 (8.7) | 25 (100) | <.001 |
| Surgical | 3 (6.5) | 0 | .55 |
Abbreviations: AVR, aortic valve replacement; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CCS, Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; NA, not applicable; NYHA, New York Heart Association; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; STS-PROM, Society of Thoracic Surgery predicted risk of mortality; TIA, transient ischemic attack.
Data are presented as number (percentage) of patients unless otherwise indicated.
P values were derived from the Fisher exact test for categorical variables and the t test for continuous variables.
Data were not available for 6 patients.
Data were not available for 2 patients.
Data were not available for 2 patients.
Data were not available for 21 patients.
Data were not available for 14 patients.